Biomarker Assessment for Eribulin Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for methods to predict the responsiveness of breast cancer patients to eribulin mesylate treatment, as current approaches lack effective predictive tools for determining patient responsiveness.
Innovation Solution
The method involves assessing the level of expression of specific biomarkers listed in Table 1, where low expression indicates responsiveness to eribulin mesylate, allowing for personalized treatment decisions by determining the biomarker levels in patient samples using techniques such as PCR, RNA detection, and protein analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment approaches are used without predictive tools, then treatment decisions are made based on general protocols, but patient responsiveness cannot be accurately predicted leading to suboptimal treatment outcomes
Solution Approach 1:
The patent applies preliminary action by identifying and measuring biomarker expression levels before initiating eribulin treatment. This allows the treatment decision to be made based on predictive information about patient responsiveness, rather than relying on trial-and-error approaches or general protocols alone.
Solution Approach 2:
The patent uses biomarkers as intermediary substances that mediate between the patient's tumor characteristics and the treatment decision. By measuring biomarker expression levels, the system translates complex tumor biology into measurable indicators that predict responsiveness to eribulin, enabling more accurate treatment selection.
2Reliability
If biomarker expression levels are measured in patient samples, then patient responsiveness can be predicted, but additional testing procedures and resources are required
Solution Approach 1:
The patent focuses on measuring specific biomarker expression levels (such as ER, PR, HER2) rather than conducting comprehensive genomic sequencing or multiple complex assays. By targeting specific parameters with established testing methods, the system achieves reliable predictions without requiring overly complex or resource-intensive procedures.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides methods for predicting the efficacy of eribulin, an analog thereof, or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate), in the treatment of a subject suffering from breast cancer by determining the level of particular biomarkers in a sample derived from the subject.